Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 495

1.

Investigation of the relationship between IL-6 and type 2 biomarkers in severe asthma.

Li X, Hastie AT, Peters MC, Hawkins GA, Phipatanakul W, Li H, Moore WC, Busse WW, Castro M, Erzurum SC, Gaston B, Israel E, Jarjour NN, Levy BD, Wenzel SE, Meyers DA, Fahy JV, Bleecker ER; NHLBI Severe Asthma Research Program (SARP) Networks.

J Allergy Clin Immunol. 2019 Sep 9. pii: S0091-6749(19)31173-X. doi: 10.1016/j.jaci.2019.08.031. [Epub ahead of print]

PMID:
31513878
2.

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis.

Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan A, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent L, Teper A.

J Allergy Clin Immunol Pract. 2019 Jul 24. pii: S2213-2198(19)30633-6. doi: 10.1016/j.jaip.2019.07.016. [Epub ahead of print]

3.

Cockroach allergen component analysis of children with or without asthma and rhinitis in an inner-city birth cohort.

Pomés A, Glesner J, Calatroni A, Visness CM, Wood RA, O'Connor GT, Kattan M, Bacharier LB, Wheatley LM, Gern JE, Busse WW; National Institute of Allergy and Infectious Diseases–funded Inner-City Asthma Consortium.

J Allergy Clin Immunol. 2019 Jun 13. pii: S0091-6749(19)30759-6. doi: 10.1016/j.jaci.2019.05.036. [Epub ahead of print]

PMID:
31201891
4.

Bronchoalveolar Lavage Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications.

Weathington N, O'Brien ME, Radder JE, Whisenant TC, Bleecker ER, Busse WW, Erzurum SC, Gaston B, Hastie AT, Jarjour NN, Meyers DA, Milosevic J, Moore WC, Tedrow JR, Trudeau JB, Wong HP, Wu W, Kaminski N, Wenzel SE, Modena BD.

Am J Respir Crit Care Med. 2019 Jun 4. doi: 10.1164/rccm.201811-2221OC. [Epub ahead of print]

PMID:
31161938
5.

Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children.

Altman MC, Gill MA, Whalen E, Babineau DC, Shao B, Liu AH, Jepson B, Gruchalla RS, O'Connor GT, Pongracic JA, Kercsmar CM, Khurana Hershey GK, Zoratti EM, Johnson CC, Teach SJ, Kattan M, Bacharier LB, Beigelman A, Sigelman SM, Presnell S, Gern JE, Gergen PJ, Wheatley LM, Togias A, Busse WW, Jackson DJ.

Nat Immunol. 2019 May;20(5):637-651. doi: 10.1038/s41590-019-0347-8. Epub 2019 Apr 8.

PMID:
30962590
6.

Biological treatments for severe asthma: A major advance in asthma care.

Busse WW.

Allergol Int. 2019 Apr;68(2):158-166. doi: 10.1016/j.alit.2019.01.004. Epub 2019 Feb 18. Review.

7.

What Are Those Neutrophils Doing in Severe Asthma Anyway?

Busse WW.

J Allergy Clin Immunol Pract. 2019 Feb;7(2):526-528. doi: 10.1016/j.jaip.2018.11.013. No abstract available.

PMID:
30717870
8.

Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions".

Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, Chatila TA, Geha RS, Gern JE, Guttman-Yassky E, Irvine AD, Kim BS, Kong HH, Lack G, Nadeau KC, Schwaninger J, Simpson A, Simpson EL, Spergel JM, Togias A, Wahn U, Wood RA, Woodfolk JA, Ziegler SF, Plaut M.

J Allergy Clin Immunol. 2019 Mar;143(3):894-913. doi: 10.1016/j.jaci.2019.01.003. Epub 2019 Jan 9.

PMID:
30639346
9.

A computerized decision support tool to implement asthma guidelines for children and adolescents.

Kercsmar CM, Sorkness CA, Calatroni A, Gergen PJ, Bloomberg GR, Gruchalla RS, Kattan M, Liu AH, O'Connor GT, Pongracic JA, Szefler SJ, Teach SJ, Wildfire JJ, Wood RA, Zoratti EM, Busse WW; National Institute of Allergy and Infectious Diseases–sponsored Inner-City Asthma Consortium.

J Allergy Clin Immunol. 2019 May;143(5):1760-1768. doi: 10.1016/j.jaci.2018.10.060. Epub 2018 Dec 5.

PMID:
30529451
10.

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.

Busse WW, Brusselle GG, Korn S, Kuna P, Magnan A, Cohen D, Bowen K, Piechowiak T, Wang MM, Colice G.

Eur Respir J. 2019 Jan 31;53(2). pii: 1800948. doi: 10.1183/13993003.00948-2018. Print 2019 Feb.

PMID:
30442714
11.

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators.

Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: Lancet Respir Med. 2019 Jan;7(1):e1.

PMID:
30416083
12.

Safety Trials of Long-Acting β2-Agonists.

Busse WW; the Joint Oversight Steering Committee for LABA Safety Combined Analysis.

N Engl J Med. 2018 Oct 11;379(15):1482. doi: 10.1056/NEJMc1810705. No abstract available.

PMID:
30304662
13.

Biological treatments for severe asthma: where do we stand?

Busse WW.

Curr Opin Allergy Clin Immunol. 2018 Dec;18(6):509-518. doi: 10.1097/ACI.0000000000000487. Review.

PMID:
30299397
14.

Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma.

Buhl R, FitzGerald JM, Busse WW.

Respir Med. 2018 Oct;143:82-90. doi: 10.1016/j.rmed.2018.08.014. Epub 2018 Aug 29. Review.

15.

Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes.

Togias A, Gergen PJ, Hu JW, Babineau DC, Wood RA, Cohen RT, Makhija MM, Khurana Hershey GK, Kercsmar CM, Gruchalla RS, Liu AH, Wang E, Kim H, Lamm CI, Bacharier LB, Pillai D, Sigelman SM, Gern JE, Busse WW.

J Allergy Clin Immunol. 2019 Mar;143(3):1003-1011.e10. doi: 10.1016/j.jaci.2018.07.041. Epub 2018 Sep 11.

PMID:
30213627
16.

Expression of corticosteroid-regulated genes by PBMCs in children with asthma.

Goleva E, Babineau DC, Gill MA, Jackson LP, Shao B, Hu Z, Liu AH, Visness CM, Sorkness CA, Leung DYM, Togias A, Busse WW.

J Allergy Clin Immunol. 2019 Mar;143(3):940-947.e6. doi: 10.1016/j.jaci.2018.06.043. Epub 2018 Jul 27.

PMID:
30059697
17.

Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists.

Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM.

N Engl J Med. 2018 Jun 28;378(26):2497-2505. doi: 10.1056/NEJMoa1716868.

18.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

19.

Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!

Busse WW.

Eur Respir J. 2018 May 10;51(5). pii: 1800730. doi: 10.1183/13993003.00730-2018. Print 2018 May. No abstract available.

PMID:
29748244
20.

"Knowing When to Hold'em and When to Fold'em" with Biological Treatments of Asthma.

Busse WW.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):883-885. doi: 10.1016/j.jaip.2018.02.005. No abstract available.

PMID:
29747991
21.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

22.

Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma.

Altman MC, Whalen E, Togias A, O'Connor GT, Bacharier LB, Bloomberg GR, Kattan M, Wood RA, Presnell S, LeBeau P, Jaffee K, Visness CM, Busse WW, Gern JE.

J Allergy Clin Immunol. 2018 Dec;142(6):1856-1866. doi: 10.1016/j.jaci.2018.02.019. Epub 2018 Mar 5.

PMID:
29518416
23.

Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects: Rome, Italy/Vatican City. 27-29 April 2017.

Traina G, Valluzzi RL, Fierro V, Riccardi C, Artesani MC, De Vuono A, Fiocchi A, Martelli AG, Ríos LA, Alcocer CR, Navarrete E, Del Rio Navarro BE, Gonzalez V, Velasco B, Perez Aviles HJ, Fernandez RJ, Pozo FC, Farhan AJ, Arshad H, Hussain A, Sharikadze O, Okhotnikova O, Alcover J, Rodriguez D, Pineda F, Dalal I, Weinbrand-Goichberg J, Benor S, Rottem M, Kivity S, Sato S, Yanagida N, Ebisawa M, Umanets T, Pineda F, Antipkin Y, Barzylovich V, Lapshyn V, Umanets T, Umanets M, Yuriev S, Pineda F, Rodriguez D, Alcover J, Bekir S, Pincock T, Vieira Hernandez A, Capriles Hulett A, Sánchez Borges M, Fabiano F, Albarran C, Goyal R, Gupta S, Gaurav G, Luskin AT, Griffin NM, Wagelie-Steffen A, Trzaskoma BL, Limb SL, Busse WW, Zeiger RS, Gonzalez-Reyes E, Casale TB, Chipps BE, Sugizaki C, Goto F, Sato S, Yanagida N, Ebisawa M, Yamaide A, Mitsunaga K, Tomiita M, Hoshioka A, Shimojo N, Pop LL, Ciucǎ IM, Tǎmaş L, Lazarescu M, Pienar C, Yamaide F, Fikri B, Sato H, Shimojo N, Okishima N, Kobayashi M, Takai M, Nishigata K, Yoda R, Oana YT, Kajiwara C, Shimodaira M, Suzuki T, Iizawa H, Kamijo K, Karmakar B, Bhattacharya SG, Blohlávková S, Kopelentová E, Víšek P, Štádler J, Šetinová I, Novobílská J, Lundelin K, Salminen S, Isolauri E, Pitt T, Flanders T, Peñalver M, Martínez P, Lluch M, Malet A, Nam YH, Jin HJ, Lee SK, Kulalert P, Sritipsukho P, Pathumanond J, Baynova K, Labella M, De Aramburu T, Prados M, Haanpää L, Aarnio J, Nermes M, Af Ursin P, Kaljonen A, Isolauri E, Bala N, Bhagwat K, Hindley J, Chapman M, Baalasubramanian S, Besednjak-Kocijančič L, SenGupta K, Bhattacharya SG, Chipps BE, Antonova E, Kong AM, Iqbal A, Teague WG, Chipps BE, Antonova E, Trzaskoma B, Ortiz B, Paknis B, Iqbal A, Rosen K, Szefler S, Alblooshi A, Al-Hammadi S, Vega A, Gutiérrez-Rivas R, Alonso AM, Beitia JM, Belén Mateo M, Cárdenas R, García-Domínguez JJ, Pitchon Dos Reis R, Gonçalves Alvim C, Andrade C, Reis A, Ribeiro H, Panaitescu Bunu C, Marusciac L, Paralescu S, Tamas P, Panitescu Bunu C, Marusciac L, Paralescu S, Tamas P, Martí Guadaño E, Escobar Bolaños C, Martí José N, Pau Casanovas P, Biarnés Rib G, Castells M, de Vicente Jiménez T, Mennini M, Riccardi C, De Angelis P, Rea F, Malamisura M, Tambucci R, Fiocchi A, Dall'Oglio L, Mennini M, Del Chierico F, Napolitano T, Reddel S, Vernocchi P, D'Ambrosio A, Putignani L, Artesani MC, Dahdah L, Fierro V, Banzato C, Echeverría Zudaire LA, Plaza AM, Bosque García M, Íbero M, Mazzina O, Fierro V, Marzano V, Riccardi C, Mazzina O, Dahdah L, Mennini M, Artesani MC, Mazzina O, Pecora V, Koch P, Valluzzi RL, Fierro V, Fiocchi A, Pecora V, Valentini D, Mennini M, Dahdah L, Mazzina O, Santamaria F, Valluzzi R, Mukherjee A, Kandhare A, Bodhankar S.

World Allergy Organ J. 2017 Nov 16;10(Suppl 2):39. doi: 10.1186/s40413-017-0170-3. eCollection 2017. No abstract available.

24.

Biologic Therapy and Asthma.

Viswanathan RK, Busse WW.

Semin Respir Crit Care Med. 2018 Feb;39(1):100-114. doi: 10.1055/s-0037-1606218. Epub 2018 Feb 10. Review.

PMID:
29427990
25.

The atopic march: Fact or folklore?

Busse WW.

Ann Allergy Asthma Immunol. 2018 Feb;120(2):116-118. doi: 10.1016/j.anai.2017.10.029. No abstract available.

PMID:
29413332
26.

Care pathways for the selection of a biologic in severe asthma.

Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, Phipatanakul W, Wahn U, Wechsler ME.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701782. doi: 10.1183/13993003.01782-2017. Print 2017 Dec. No abstract available.

27.

Obstruction phenotype as a predictor of asthma severity and instability in children.

Sorkness RL, Zoratti EM, Kattan M, Gergen PJ, Evans MD, Visness CM, Gill M, Khurana Hershey GK, Kercsmar CM, Liu AH, O'Connor GT, Pongracic JA, Pillai D, Sorkness CA, Togias A, Wood RA, Busse WW.

J Allergy Clin Immunol. 2018 Oct;142(4):1090-1099.e4. doi: 10.1016/j.jaci.2017.09.047. Epub 2017 Nov 14.

PMID:
29146272
28.

Are Biotherapeutics Revolutionizing Treatment of "Allergic" Diseases?

Busse WW.

J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1517-1518. doi: 10.1016/j.jaip.2017.08.017. No abstract available.

PMID:
29122153
29.

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

Chipps BE, Zeiger RS, Luskin AT, Busse WW, Trzaskoma BL, Antonova EN, Pazwash H, Limb SL, Solari PG, Griffin NM, Casale TB.

Ann Allergy Asthma Immunol. 2017 Dec;119(6):524-532.e2. doi: 10.1016/j.anai.2017.09.056. Epub 2017 Oct 18.

30.

New and Anticipated Therapies for Severe Asthma.

Peters SP, Busse WW.

J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5S):S15-S24. doi: 10.1016/j.jaip.2017.07.008. Review.

PMID:
28888244
31.

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.

Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, Gern JE, Togias A, Busse WW.

J Allergy Clin Immunol. 2018 May;141(5):1735-1743.e9. doi: 10.1016/j.jaci.2017.07.035. Epub 2017 Sep 1.

32.

Corrigendum to "Mind-body interactions in the regulation of airway inflammation in asthma: A PET study of acute and chronic stress" [Brain Behav. Immun. 58 (2016) 18-30].

Rosenkranz MA, Esnault S, Christian BT, Crisafi G, Gresham LK, Higgins AT, Moore MN, Moore SM, Weng HY, Salk RH, Busse WW, Davidson RJ.

Brain Behav Immun. 2018 Jan;67:398-401. doi: 10.1016/j.bbi.2017.08.009. Epub 2017 Aug 20. No abstract available.

33.

Asthma Exacerbations: Pathogenesis, Prevention, and Treatment.

Castillo JR, Peters SP, Busse WW.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):918-927. doi: 10.1016/j.jaip.2017.05.001. Review.

34.

Endotypes of difficult-to-control asthma in inner-city African American children.

Brown KR, Krouse RZ, Calatroni A, Visness CM, Sivaprasad U, Kercsmar CM, Matsui EC, West JB, Makhija MM, Gill MA, Kim H, Kattan M, Pillai D, Gern JE, Busse WW, Togias A, Liu AH, Khurana Hershey GK.

PLoS One. 2017 Jul 7;12(7):e0180778. doi: 10.1371/journal.pone.0180778. eCollection 2017.

35.

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.

Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, Gruchalla RS, Kattan M, Kercsmar CM, Khurana Hershey G, Kim H, Lebeau P, Liu AH, Szefler SJ, Teach SJ, West JB, Wildfire J, Pongracic JA, Gern JE.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):985-992. doi: 10.1164/rccm.201701-0120OC.

36.

A role for neutrophils in asthma exacerbations.

Busse WW.

Nat Med. 2017 Jun 6;23(6):658-659. doi: 10.1038/nm.4351. No abstract available.

PMID:
28586342
37.

A Deep Dive into Asthma Transcriptomics. Lessons from U-BIOPRED.

Altman MC, Busse WW.

Am J Respir Crit Care Med. 2017 May 15;195(10):1279-1280. doi: 10.1164/rccm.201611-2387ED. No abstract available.

PMID:
28504594
38.

Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.

Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Rosén K, Trzaskoma B, Busse WW.

J Allergy Clin Immunol. 2017 May;139(5):1431-1444. doi: 10.1016/j.jaci.2017.03.002. Review.

39.

Biologicals for asthma in patients with asthma-COPD overlap.

Busse WW.

Lancet Respir Med. 2017 Mar;5(3):175-177. doi: 10.1016/S2213-2600(17)30055-3. Review. No abstract available.

PMID:
28266326
40.

Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index.

Hoch HE, Calatroni A, West JB, Liu AH, Gergen PJ, Gruchalla RS, Khurana Hershey GK, Kercsmar CM, Kim H, Lamm CI, Makhija MM, Mitchell HE, Teach SJ, Wildfire JJ, Busse WW, Szefler SJ.

J Allergy Clin Immunol. 2017 Oct;140(4):1130-1137.e5. doi: 10.1016/j.jaci.2017.01.026. Epub 2017 Feb 24.

41.

Reply.

Liu AH, Zoratti EM, Pongracic JA, Babineau DC, Visness CM, Gergen PJ, Togias A, Busse WW; Inner-City Asthma Consortium.

J Allergy Clin Immunol. 2017 Apr;139(4):1408-1409. doi: 10.1016/j.jaci.2016.12.962. Epub 2017 Feb 22. No abstract available.

PMID:
28237730
42.

Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies.

Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, Jacobs JS, Kraft M, Martin RJ, Nair P, Wechsler ME.

J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2S):S1-S14. doi: 10.1016/j.jaip.2016.11.029. Epub 2017 Jan 29. Review.

PMID:
28143691
43.

Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease.

Modena BD, Bleecker ER, Busse WW, Erzurum SC, Gaston BM, Jarjour NN, Meyers DA, Milosevic J, Tedrow JR, Wu W, Kaminski N, Wenzel SE.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1449-1463. doi: 10.1164/rccm.201607-1407OC.

44.

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.

Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM.

Lancet. 2017 Jan 14;389(10065):157-166. doi: 10.1016/S0140-6736(16)31399-X. Epub 2016 Nov 30.

PMID:
27912982
45.

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.

O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW.

Respir Res. 2016 Nov 24;17(1):157.

46.

Anaphylaxis Conundrum: A Trojan Horse Phenomenon.

Esquivel A, Busse WW.

J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):325-329. doi: 10.1016/j.jaip.2016.08.008. Epub 2016 Oct 17. Review.

47.

The nasal methylome and childhood atopic asthma.

Yang IV, Pedersen BS, Liu AH, O'Connor GT, Pillai D, Kattan M, Misiak RT, Gruchalla R, Szefler SJ, Khurana Hershey GK, Kercsmar C, Richards A, Stevens AD, Kolakowski CA, Makhija M, Sorkness CA, Krouse RZ, Visness C, Davidson EJ, Hennessy CE, Martin RJ, Togias A, Busse WW, Schwartz DA.

J Allergy Clin Immunol. 2017 May;139(5):1478-1488. doi: 10.1016/j.jaci.2016.07.036. Epub 2016 Oct 13.

48.

Pathways through which asthma risk factors contribute to asthma severity in inner-city children.

Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O'Connor GT, Wood RA, Khurana Hershey GK, Kercsmar CM, Gruchalla RS, Kattan M, Teach SJ, Makhija M, Pillai D, Lamm CI, Gern JE, Sigelman SM, Gergen PJ, Togias A, Visness CM, Busse WW.

J Allergy Clin Immunol. 2016 Oct;138(4):1042-1050. doi: 10.1016/j.jaci.2016.06.060.

49.

Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents.

Pongracic JA, Krouse RZ, Babineau DC, Zoratti EM, Cohen RT, Wood RA, Khurana Hershey GK, Kercsmar CM, Gruchalla RS, Kattan M, Teach SJ, Johnson CC, Bacharier LB, Gern JE, Sigelman SM, Gergen PJ, Togias A, Visness CM, Busse WW, Liu AH.

J Allergy Clin Immunol. 2016 Oct;138(4):1030-1041. doi: 10.1016/j.jaci.2016.06.059.

50.

Asthma phenotypes in inner-city children.

Zoratti EM, Krouse RZ, Babineau DC, Pongracic JA, O'Connor GT, Wood RA, Khurana Hershey GK, Kercsmar CM, Gruchalla RS, Kattan M, Teach SJ, Sigelman SM, Gergen PJ, Togias A, Visness CM, Busse WW, Liu AH.

J Allergy Clin Immunol. 2016 Oct;138(4):1016-1029. doi: 10.1016/j.jaci.2016.06.061.

Supplemental Content

Loading ...
Support Center